img

Global Rare Disease Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Rare Disease Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Rare Disease Drug market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Rare Disease Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Rare Disease Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Rare Disease Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Rare Disease Drug include Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company and Novo Nordisk A/S, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Rare Disease Drug, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Rare Disease Drug by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Rare Disease Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Rare Disease Drug market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Takeda
Amgen, Inc.
Deciphera
Atara Biotherapeutics
ProQR
By Type
Above 1‰
0.65‰～1‰
Below 0.1‰
By Application
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Rare Disease Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Rare Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rare Disease Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Rare Disease Drug Definition
1.2 Market by Type
1.2.1 Global Rare Disease Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Above 1‰
1.2.3 0.65‰～1‰
1.2.4 Below 0.1‰
1.3 Market Segment by Application
1.3.1 Global Rare Disease Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Speciality Pharmacies
1.3.4 Retail pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Rare Disease Drug Sales
2.1 Global Rare Disease Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Rare Disease Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Rare Disease Drug Revenue by Region
2.3.1 Global Rare Disease Drug Revenue by Region (2018-2023)
2.3.2 Global Rare Disease Drug Revenue by Region (2024-2034)
2.4 Global Rare Disease Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Rare Disease Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Rare Disease Drug Sales Quantity by Region
2.6.1 Global Rare Disease Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Rare Disease Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Rare Disease Drug Sales Quantity by Manufacturers
3.1.1 Global Rare Disease Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Rare Disease Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Rare Disease Drug Sales in 2024
3.2 Global Rare Disease Drug Revenue by Manufacturers
3.2.1 Global Rare Disease Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Rare Disease Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Rare Disease Drug Revenue in 2024
3.3 Global Rare Disease Drug Sales Price by Manufacturers
3.4 Global Key Players of Rare Disease Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Rare Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Rare Disease Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Rare Disease Drug, Product Offered and Application
3.8 Global Key Manufacturers of Rare Disease Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Rare Disease Drug Sales Quantity by Type
4.1.1 Global Rare Disease Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Rare Disease Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Rare Disease Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Rare Disease Drug Revenue by Type
4.2.1 Global Rare Disease Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Rare Disease Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Rare Disease Drug Revenue Market Share by Type (2018-2034)
4.3 Global Rare Disease Drug Price by Type
4.3.1 Global Rare Disease Drug Price by Type (2018-2023)
4.3.2 Global Rare Disease Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Rare Disease Drug Sales Quantity by Application
5.1.1 Global Rare Disease Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Rare Disease Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Rare Disease Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Rare Disease Drug Revenue by Application
5.2.1 Global Rare Disease Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Rare Disease Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Rare Disease Drug Revenue Market Share by Application (2018-2034)
5.3 Global Rare Disease Drug Price by Application
5.3.1 Global Rare Disease Drug Price by Application (2018-2023)
5.3.2 Global Rare Disease Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Rare Disease Drug Sales by Company
6.1.1 North America Rare Disease Drug Revenue by Company (2018-2023)
6.1.2 North America Rare Disease Drug Sales Quantity by Company (2018-2023)
6.2 North America Rare Disease Drug Market Size by Type
6.2.1 North America Rare Disease Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Rare Disease Drug Revenue by Type (2018-2034)
6.3 North America Rare Disease Drug Market Size by Application
6.3.1 North America Rare Disease Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Rare Disease Drug Revenue by Application (2018-2034)
6.4 North America Rare Disease Drug Market Size by Country
6.4.1 North America Rare Disease Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Rare Disease Drug Revenue by Country (2018-2034)
6.4.3 North America Rare Disease Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Rare Disease Drug Sales by Company
7.1.1 Europe Rare Disease Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Rare Disease Drug Revenue by Company (2018-2023)
7.2 Europe Rare Disease Drug Market Size by Type
7.2.1 Europe Rare Disease Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Rare Disease Drug Revenue by Type (2018-2034)
7.3 Europe Rare Disease Drug Market Size by Application
7.3.1 Europe Rare Disease Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Rare Disease Drug Revenue by Application (2018-2034)
7.4 Europe Rare Disease Drug Market Size by Country
7.4.1 Europe Rare Disease Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Rare Disease Drug Revenue by Country (2018-2034)
7.4.3 Europe Rare Disease Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Rare Disease Drug Sales by Company
8.1.1 China Rare Disease Drug Sales Quantity by Company (2018-2023)
8.1.2 China Rare Disease Drug Revenue by Company (2018-2023)
8.2 China Rare Disease Drug Market Size by Type
8.2.1 China Rare Disease Drug Sales Quantity by Type (2018-2034)
8.2.2 China Rare Disease Drug Revenue by Type (2018-2034)
8.3 China Rare Disease Drug Market Size by Application
8.3.1 China Rare Disease Drug Sales Quantity by Application (2018-2034)
8.3.2 China Rare Disease Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Rare Disease Drug Sales by Company
9.1.1 APAC Rare Disease Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Rare Disease Drug Revenue by Company (2018-2023)
9.2 APAC Rare Disease Drug Market Size by Type
9.2.1 APAC Rare Disease Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Rare Disease Drug Revenue by Type (2018-2034)
9.3 APAC Rare Disease Drug Market Size by Application
9.3.1 APAC Rare Disease Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Rare Disease Drug Revenue by Application (2018-2034)
9.4 APAC Rare Disease Drug Market Size by Region
9.4.1 APAC Rare Disease Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Rare Disease Drug Revenue by Region (2018-2034)
9.4.3 APAC Rare Disease Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Rare Disease Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Rare Disease Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Rare Disease Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Rare Disease Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Rare Disease Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Rare Disease Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Rare Disease Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Rare Disease Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Rare Disease Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Information
11.1.2 Novartis AG Overview
11.1.3 Novartis AG Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Novartis AG Rare Disease Drug Products and Services
11.1.5 Novartis AG Rare Disease Drug SWOT Analysis
11.1.6 Novartis AG Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Information
11.2.2 Bristol-Myers Squibb Company Overview
11.2.3 Bristol-Myers Squibb Company Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Bristol-Myers Squibb Company Rare Disease Drug Products and Services
11.2.5 Bristol-Myers Squibb Company Rare Disease Drug SWOT Analysis
11.2.6 Bristol-Myers Squibb Company Recent Developments
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Information
11.3.2 Celgene Corporation Overview
11.3.3 Celgene Corporation Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Celgene Corporation Rare Disease Drug Products and Services
11.3.5 Celgene Corporation Rare Disease Drug SWOT Analysis
11.3.6 Celgene Corporation Recent Developments
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Company Information
11.4.2 F. Hoffmann-La Roche Ltd. Overview
11.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Products and Services
11.4.5 F. Hoffmann-La Roche Ltd. Rare Disease Drug SWOT Analysis
11.4.6 F. Hoffmann-La Roche Ltd. Recent Developments
11.5 Pfizer, Inc.
11.5.1 Pfizer, Inc. Company Information
11.5.2 Pfizer, Inc. Overview
11.5.3 Pfizer, Inc. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Pfizer, Inc. Rare Disease Drug Products and Services
11.5.5 Pfizer, Inc. Rare Disease Drug SWOT Analysis
11.5.6 Pfizer, Inc. Recent Developments
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Company Information
11.6.2 Sanofi S.A. Overview
11.6.3 Sanofi S.A. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Sanofi S.A. Rare Disease Drug Products and Services
11.6.5 Sanofi S.A. Rare Disease Drug SWOT Analysis
11.6.6 Sanofi S.A. Recent Developments
11.7 Alexion Pharmaceuticals, Inc.
11.7.1 Alexion Pharmaceuticals, Inc. Company Information
11.7.2 Alexion Pharmaceuticals, Inc. Overview
11.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Products and Services
11.7.5 Alexion Pharmaceuticals, Inc. Rare Disease Drug SWOT Analysis
11.7.6 Alexion Pharmaceuticals, Inc. Recent Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Information
11.8.2 Eli Lilly and Company Overview
11.8.3 Eli Lilly and Company Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Eli Lilly and Company Rare Disease Drug Products and Services
11.8.5 Eli Lilly and Company Rare Disease Drug SWOT Analysis
11.8.6 Eli Lilly and Company Recent Developments
11.9 Novo Nordisk A/S
11.9.1 Novo Nordisk A/S Company Information
11.9.2 Novo Nordisk A/S Overview
11.9.3 Novo Nordisk A/S Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Novo Nordisk A/S Rare Disease Drug Products and Services
11.9.5 Novo Nordisk A/S Rare Disease Drug SWOT Analysis
11.9.6 Novo Nordisk A/S Recent Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Company Information
11.10.2 AstraZeneca Overview
11.10.3 AstraZeneca Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 AstraZeneca Rare Disease Drug Products and Services
11.10.5 AstraZeneca Rare Disease Drug SWOT Analysis
11.10.6 AstraZeneca Recent Developments
11.11 Eisai Co., Ltd.
11.11.1 Eisai Co., Ltd. Company Information
11.11.2 Eisai Co., Ltd. Overview
11.11.3 Eisai Co., Ltd. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Eisai Co., Ltd. Rare Disease Drug Products and Services
11.11.5 Eisai Co., Ltd. Recent Developments
11.12 Daiichi Sankyo Company Limited
11.12.1 Daiichi Sankyo Company Limited Company Information
11.12.2 Daiichi Sankyo Company Limited Overview
11.12.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Daiichi Sankyo Company Limited Rare Disease Drug Products and Services
11.12.5 Daiichi Sankyo Company Limited Recent Developments
11.13 Bayer AG
11.13.1 Bayer AG Company Information
11.13.2 Bayer AG Overview
11.13.3 Bayer AG Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Bayer AG Rare Disease Drug Products and Services
11.13.5 Bayer AG Recent Developments
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Company Information
11.14.2 GlaxoSmithKline Overview
11.14.3 GlaxoSmithKline Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 GlaxoSmithKline Rare Disease Drug Products and Services
11.14.5 GlaxoSmithKline Recent Developments
11.15 Merck & Co., Inc.
11.15.1 Merck & Co., Inc. Company Information
11.15.2 Merck & Co., Inc. Overview
11.15.3 Merck & Co., Inc. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Merck & Co., Inc. Rare Disease Drug Products and Services
11.15.5 Merck & Co., Inc. Recent Developments
11.16 Johnson & Johnson
11.16.1 Johnson & Johnson Company Information
11.16.2 Johnson & Johnson Overview
11.16.3 Johnson & Johnson Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 Johnson & Johnson Rare Disease Drug Products and Services
11.16.5 Johnson & Johnson Recent Developments
11.17 Biogen, Inc.
11.17.1 Biogen, Inc. Company Information
11.17.2 Biogen, Inc. Overview
11.17.3 Biogen, Inc. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Biogen, Inc. Rare Disease Drug Products and Services
11.17.5 Biogen, Inc. Recent Developments
11.18 Takeda
11.18.1 Takeda Company Information
11.18.2 Takeda Overview
11.18.3 Takeda Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Takeda Rare Disease Drug Products and Services
11.18.5 Takeda Recent Developments
11.19 Amgen, Inc.
11.19.1 Amgen, Inc. Company Information
11.19.2 Amgen, Inc. Overview
11.19.3 Amgen, Inc. Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.19.4 Amgen, Inc. Rare Disease Drug Products and Services
11.19.5 Amgen, Inc. Recent Developments
11.20 Deciphera
11.20.1 Deciphera Company Information
11.20.2 Deciphera Overview
11.20.3 Deciphera Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.20.4 Deciphera Rare Disease Drug Products and Services
11.20.5 Deciphera Recent Developments
11.21 Atara Biotherapeutics
11.21.1 Atara Biotherapeutics Company Information
11.21.2 Atara Biotherapeutics Overview
11.21.3 Atara Biotherapeutics Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.21.4 Atara Biotherapeutics Rare Disease Drug Products and Services
11.21.5 Atara Biotherapeutics Recent Developments
11.22 ProQR
11.22.1 ProQR Company Information
11.22.2 ProQR Overview
11.22.3 ProQR Rare Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.22.4 ProQR Rare Disease Drug Products and Services
11.22.5 ProQR Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Rare Disease Drug Value Chain Analysis
12.2 Rare Disease Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Rare Disease Drug Production Mode & Process
12.4 Rare Disease Drug Sales and Marketing
12.4.1 Rare Disease Drug Sales Channels
12.4.2 Rare Disease Drug Distributors
12.5 Rare Disease Drug Customers
13 Market Dynamics
13.1 Rare Disease Drug Industry Trends
13.2 Rare Disease Drug Market Drivers
13.3 Rare Disease Drug Market Challenges
13.4 Rare Disease Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Rare Disease Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Above 1‰
Table 3. Major Manufacturers of 0.65‰～1‰
Table 4. Major Manufacturers of Below 0.1‰
Table 5. Global Rare Disease Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Rare Disease Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Rare Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Rare Disease Drug Revenue Market Share by Region (2018-2023)
Table 9. Global Rare Disease Drug Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Rare Disease Drug Revenue Market Share by Region (2024-2034)
Table 11. Global Rare Disease Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Doses)
Table 12. Global Rare Disease Drug Sales by Region (2018-2023) & (K Doses)
Table 13. Global Rare Disease Drug Sales Market Share by Region (2018-2023)
Table 14. Global Rare Disease Drug Sales by Region (2024-2034) & (K Doses)
Table 15. Global Rare Disease Drug Sales Market Share by Region (2024-2034)
Table 16. Global Rare Disease Drug Sales Quantity by Manufacturers (2018-2023) & (K Doses)
Table 17. Global Rare Disease Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 18. Global Rare Disease Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Rare Disease Drug Revenue Share by Manufacturers (2018-2023)
Table 20. Global Rare Disease Drug Price by Manufacturers 2018-2023 (USD/Dose)
Table 21. Global Key Players of Rare Disease Drug, Industry Ranking, 2021 VS 2024
Table 22. Global Rare Disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Rare Disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Rare Disease Drug as of 2024)
Table 24. Global Key Manufacturers of Rare Disease Drug, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Rare Disease Drug, Product Offered and Application
Table 26. Global Key Manufacturers of Rare Disease Drug, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Rare Disease Drug Sales Quantity by Type (2018-2023) & (K Doses)
Table 29. Global Rare Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 30. Global Rare Disease Drug Sales Quantity Share by Type (2018-2023)
Table 31. Global Rare Disease Drug Sales Quantity Share by Type (2024-2034)
Table 32. Global Rare Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Rare Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Rare Disease Drug Revenue Share by Type (2018-2023)
Table 35. Global Rare Disease Drug Revenue Share by Type (2024-2034)
Table 36. Rare Disease Drug Price by Type (2018-2023) & (USD/Dose)
Table 37. Global Rare Disease Drug Price Forecast by Type (2024-2034) & (USD/Dose)
Table 38. Global Rare Disease Drug Sales Quantity by Application (2018-2023) & (K Doses)
Table 39. Global Rare Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 40. Global Rare Disease Drug Sales Quantity Share by Application (2018-2023)
Table 41. Global Rare Disease Drug Sales Quantity Share by Application (2024-2034)
Table 42. Global Rare Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Rare Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Rare Disease Drug Revenue Share by Application (2018-2023)
Table 45. Global Rare Disease Drug Revenue Share by Application (2024-2034)
Table 46. Rare Disease Drug Price by Application (2018-2023) & (USD/Dose)
Table 47. Global Rare Disease Drug Price Forecast by Application (2024-2034) & (USD/Dose)
Table 48. North America Rare Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 49. North America Rare Disease Drug Sales Quantity by Company (2018-2023) & (K Doses)
Table 50. North America Rare Disease Drug Sales Quantity by Type (2018-2023) & (K Doses)
Table 51. North America Rare Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 52. North America Rare Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 53. North America Rare Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Rare Disease Drug Sales Quantity by Application (2018-2023) & (K Doses)
Table 55. North America Rare Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 56. North America Rare Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 57. North America Rare Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Rare Disease Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 59. North America Rare Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 60. North America Rare Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Rare Disease Drug Sales Quantity by Country (2018-2023) & (K Doses)
Table 62. North America Rare Disease Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 63. Europe Rare Disease Drug Sales Quantity by Company (2018-2023) & (K Doses)
Table 64. Europe Rare Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 65. Europe Rare Disease Drug Sales Quantity by Type (2018-2023) & (K Doses)
Table 66. Europe Rare Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 67. Europe Rare Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 68. Europe Rare Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Rare Disease Drug Sales Quantity by Application (2018-2023) & (K Doses)
Table 70. Europe Rare Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 71. Europe Rare Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 72. Europe Rare Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Rare Disease Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 74. Europe Rare Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 75. Europe Rare Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Rare Disease Drug Sales Quantity by Country (2018-2023) & (K Doses)
Table 77. Europe Rare Disease Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 78. China Rare Disease Drug Sales Quantity by Company (2018-2023) & (K Doses)
Table 79. China Rare Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 80. China Rare Disease Drug Sales Quantity by Type (2018-2023) & (K Doses)
Table 81. China Rare Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 82. China Rare Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 83. China Rare Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Rare Disease Drug Sales Quantity by Application (2018-2023) & (K Doses)
Table 85. China Rare Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 86. China Rare Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 87. China Rare Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Rare Disease Drug Sales Quantity by Company (2018-2023) & (K Doses)
Table 89. APAC Rare Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 90. APAC Rare Disease Drug Sales Quantity by Type (2018-2023) & (K Doses)
Table 91. APAC Rare Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 92. APAC Rare Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 93. APAC Rare Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Rare Disease Drug Sales Quantity by Application (2018-2023) & (K Doses)
Table 95. APAC Rare Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 96. APAC Rare Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 97. APAC Rare Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Rare Disease Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 99. APAC Rare Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 100. APAC Rare Disease Drug Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Rare Disease Drug Sales Quantity by Region (2018-2023) & (K Doses)
Table 102. APAC Rare Disease Drug Sales Quantity by Region (2024-2034) & (K Doses)
Table 103. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Company (2018-2023) & (K Doses)
Table 104. Middle East, Africa and Latin America Rare Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Type (2018-2023) & (K Doses)
Table 106. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 107. Middle East, Africa and Latin America Rare Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Rare Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Application (2018-2023) & (K Doses)
Table 110. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 111. Middle East, Africa and Latin America Rare Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Rare Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Rare Disease Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Rare Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Rare Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Country (2018-2023) & (K Doses)
Table 117. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 118. Novartis AG Company Information
Table 119. Novartis AG Description and Overview
Table 120. Novartis AG Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 121. Novartis AG Rare Disease Drug Product and Services
Table 122. Novartis AG Rare Disease Drug SWOT Analysis
Table 123. Novartis AG Recent Developments
Table 124. Bristol-Myers Squibb Company Company Information
Table 125. Bristol-Myers Squibb Company Description and Overview
Table 126. Bristol-Myers Squibb Company Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 127. Bristol-Myers Squibb Company Rare Disease Drug Product and Services
Table 128. Bristol-Myers Squibb Company Rare Disease Drug SWOT Analysis
Table 129. Bristol-Myers Squibb Company Recent Developments
Table 130. Celgene Corporation Company Information
Table 131. Celgene Corporation Description and Overview
Table 132. Celgene Corporation Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 133. Celgene Corporation Rare Disease Drug Product and Services
Table 134. Celgene Corporation Rare Disease Drug SWOT Analysis
Table 135. Celgene Corporation Recent Developments
Table 136. F. Hoffmann-La Roche Ltd. Company Information
Table 137. F. Hoffmann-La Roche Ltd. Description and Overview
Table 138. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 139. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product and Services
Table 140. F. Hoffmann-La Roche Ltd. Rare Disease Drug SWOT Analysis
Table 141. F. Hoffmann-La Roche Ltd. Recent Developments
Table 142. Pfizer, Inc. Company Information
Table 143. Pfizer, Inc. Description and Overview
Table 144. Pfizer, Inc. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 145. Pfizer, Inc. Rare Disease Drug Product and Services
Table 146. Pfizer, Inc. Rare Disease Drug SWOT Analysis
Table 147. Pfizer, Inc. Recent Developments
Table 148. Sanofi S.A. Company Information
Table 149. Sanofi S.A. Description and Overview
Table 150. Sanofi S.A. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 151. Sanofi S.A. Rare Disease Drug Product and Services
Table 152. Sanofi S.A. Rare Disease Drug SWOT Analysis
Table 153. Sanofi S.A. Recent Developments
Table 154. Alexion Pharmaceuticals, Inc. Company Information
Table 155. Alexion Pharmaceuticals, Inc. Description and Overview
Table 156. Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 157. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product and Services
Table 158. Alexion Pharmaceuticals, Inc. Rare Disease Drug SWOT Analysis
Table 159. Alexion Pharmaceuticals, Inc. Recent Developments
Table 160. Eli Lilly and Company Company Information
Table 161. Eli Lilly and Company Description and Overview
Table 162. Eli Lilly and Company Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 163. Eli Lilly and Company Rare Disease Drug Product and Services
Table 164. Eli Lilly and Company Rare Disease Drug SWOT Analysis
Table 165. Eli Lilly and Company Recent Developments
Table 166. Novo Nordisk A/S Company Information
Table 167. Novo Nordisk A/S Description and Overview
Table 168. Novo Nordisk A/S Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 169. Novo Nordisk A/S Rare Disease Drug Product and Services
Table 170. Novo Nordisk A/S Rare Disease Drug SWOT Analysis
Table 171. Novo Nordisk A/S Recent Developments
Table 172. AstraZeneca Company Information
Table 173. AstraZeneca Description and Overview
Table 174. AstraZeneca Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 175. AstraZeneca Rare Disease Drug Product and Services
Table 176. AstraZeneca Rare Disease Drug SWOT Analysis
Table 177. AstraZeneca Recent Developments
Table 178. Eisai Co., Ltd. Company Information
Table 179. Eisai Co., Ltd. Description and Overview
Table 180. Eisai Co., Ltd. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 181. Eisai Co., Ltd. Rare Disease Drug Product and Services
Table 182. Eisai Co., Ltd. Recent Developments
Table 183. Daiichi Sankyo Company Limited Company Information
Table 184. Daiichi Sankyo Company Limited Description and Overview
Table 185. Daiichi Sankyo Company Limited Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 186. Daiichi Sankyo Company Limited Rare Disease Drug Product and Services
Table 187. Daiichi Sankyo Company Limited Recent Developments
Table 188. Bayer AG Company Information
Table 189. Bayer AG Description and Overview
Table 190. Bayer AG Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 191. Bayer AG Rare Disease Drug Product and Services
Table 192. Bayer AG Recent Developments
Table 193. GlaxoSmithKline Company Information
Table 194. GlaxoSmithKline Description and Overview
Table 195. GlaxoSmithKline Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 196. GlaxoSmithKline Rare Disease Drug Product and Services
Table 197. GlaxoSmithKline Recent Developments
Table 198. Merck & Co., Inc. Company Information
Table 199. Merck & Co., Inc. Description and Overview
Table 200. Merck & Co., Inc. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 201. Merck & Co., Inc. Rare Disease Drug Product and Services
Table 202. Merck & Co., Inc. Recent Developments
Table 203. Johnson & Johnson Company Information
Table 204. Johnson & Johnson Description and Overview
Table 205. Johnson & Johnson Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 206. Johnson & Johnson Rare Disease Drug Product and Services
Table 207. Johnson & Johnson Recent Developments
Table 208. Biogen, Inc. Company Information
Table 209. Biogen, Inc. Description and Overview
Table 210. Biogen, Inc. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 211. Biogen, Inc. Rare Disease Drug Product and Services
Table 212. Biogen, Inc. Recent Developments
Table 213. Takeda Company Information
Table 214. Takeda Description and Overview
Table 215. Takeda Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 216. Takeda Rare Disease Drug Product and Services
Table 217. Takeda Recent Developments
Table 218. Amgen, Inc. Company Information
Table 219. Amgen, Inc. Description and Overview
Table 220. Amgen, Inc. Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 221. Amgen, Inc. Rare Disease Drug Product and Services
Table 222. Amgen, Inc. Recent Developments
Table 223. Deciphera Company Information
Table 224. Deciphera Description and Overview
Table 225. Deciphera Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 226. Deciphera Rare Disease Drug Product and Services
Table 227. Deciphera Recent Developments
Table 228. Atara Biotherapeutics Company Information
Table 229. Atara Biotherapeutics Description and Overview
Table 230. Atara Biotherapeutics Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 231. Atara Biotherapeutics Rare Disease Drug Product and Services
Table 232. Atara Biotherapeutics Recent Developments
Table 233. ProQR Company Information
Table 234. ProQR Description and Overview
Table 235. ProQR Rare Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 236. ProQR Rare Disease Drug Product and Services
Table 237. ProQR Recent Developments
Table 238. Key Raw Materials Lists
Table 239. Raw Materials Key Suppliers Lists
Table 240. Rare Disease Drug Distributors List
Table 241. Rare Disease Drug Customers List
Table 242. Rare Disease Drug Market Trends
Table 243. Rare Disease Drug Market Drivers
Table 244. Rare Disease Drug Market Challenges
Table 245. Rare Disease Drug Market Restraints
Table 246. Research Programs/Design for This Report
Table 247. Key Data Information from Secondary Sources
Table 248. Key Data Information from Primary Sources
List of Figures
Figure 1. Rare Disease Drug Product Picture
Figure 2. Global Rare Disease Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Rare Disease Drug Market Share by Type in 2024 & 2034
Figure 4. Above 1‰ Product Picture
Figure 5. 0.65‰～1‰ Product Picture
Figure 6. Below 0.1‰ Product Picture
Figure 7. Global Rare Disease Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 8. Global Rare Disease Drug Market Share by Application in 2024 & 2034
Figure 9. Hospital Pharmacies
Figure 10. Speciality Pharmacies
Figure 11. Retail pharmacies
Figure 12. Others
Figure 13. Rare Disease Drug Report Years Considered
Figure 14. Global Rare Disease Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Rare Disease Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Rare Disease Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 17. Global Rare Disease Drug Sales Quantity 2018-2034 (K Doses)
Figure 18. Global Rare Disease Drug Sales Quantity Market Share by Region (2018-2023)
Figure 19. Global Rare Disease Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Rare Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 21. North America Rare Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Rare Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 23. Europe Rare Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Rare Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 25. China Rare Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Rare Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 27. APAC Rare Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 29. Middle East, Africa and Latin America Rare Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Rare Disease Drug Sales Quantity in 2024
Figure 31. The Top 10 and Top 5 Players Market Share by Rare Disease Drug Revenue in 2024
Figure 32. Rare Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 33. Global Rare Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Rare Disease Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Rare Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Rare Disease Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Rare Disease Drug Revenue Market Share by Company in 2024
Figure 38. North America Rare Disease Drug Sales Quantity Market Share by Company in 2024
Figure 39. North America Rare Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Rare Disease Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Rare Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Rare Disease Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Rare Disease Drug Revenue Share by Country (2018-2034)
Figure 44. North America Rare Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Rare Disease Drug Sales Quantity Market Share by Company in 2024
Figure 48. Europe Rare Disease Drug Revenue Market Share by Company in 2024
Figure 49. Europe Rare Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Rare Disease Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Rare Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Rare Disease Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Rare Disease Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Rare Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Rare Disease Drug Sales Quantity Market Share by Company in 2024
Figure 61. China Rare Disease Drug Revenue Market Share by Company in 2024
Figure 62. China Rare Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Rare Disease Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Rare Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Rare Disease Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Rare Disease Drug Sales Quantity Market Share by Company in 2024
Figure 67. APAC Rare Disease Drug Revenue Market Share by Company in 2024
Figure 68. APAC Rare Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Rare Disease Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Rare Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Rare Disease Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Rare Disease Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Rare Disease Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Rare Disease Drug Revenue Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Rare Disease Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Rare Disease Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Rare Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Rare Disease Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Rare Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Rare Disease Drug Value Chain
Figure 93. Rare Disease Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries